Radiotherapy for lung cancer RCR consensus statements
Date of next review: 2023
The RCR consensus process was initially developed in 2016 to help reduce variation in UK radiotherapy practice. The lung cancer statements should serve as a practical stimulus for lung cancer teams to review their current radiotherapy service to ensure that they are able to deliver optimal treatment for their patients. They should be adopted in parallel with those in the National Institute for Health and Care Excellence (NICE) lung cancer guideline.
If all the recommendations are adopted in each centre then outcomes for UK lung cancer patients will undoubtedly improve.
The areas covered by the consensus statements in this document are:
- Optimising patients for radical radiotherapy for lung cancer
- Technical aspects of radical radiotherapy for lung cancer
- Stereotactic ablative radiotherapy (SABR) for early stage non-small cell lung cancer (NSCLC)
- Combined-modality treatment of locally advanced NSCLC
- Radiotherapy for advanced lung cancer
- Treatment of small cell lung cancer (SCLC)